Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Net Margin for 10 consecutive years, with 34.53% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 491.0% year-over-year to 34.53%, compared with a TTM value of 36.39% through Dec 2025, up 306.0%, and an annual FY2025 reading of 36.39%, up 306.0% over the prior year.
  • Net Margin was 34.53% for Q4 2025 at Catalyst Pharmaceuticals, down from 35.57% in the prior quarter.
  • Across five years, Net Margin topped out at 71.16% in Q4 2022 and bottomed at 29.96% in Q3 2023.
  • Average Net Margin over 5 years is 31.42%, with a median of 34.31% recorded in 2024.
  • The sharpest move saw Net Margin tumbled -11910bps in 2021, then soared 6406bps in 2024.
  • Year by year, Net Margin stood at 24.3% in 2021, then skyrocketed by 193bps to 71.16% in 2022, then crashed by -78bps to 15.41% in 2023, then skyrocketed by 156bps to 39.44% in 2024, then fell by -12bps to 34.53% in 2025.
  • Business Quant data shows Net Margin for CPRX at 34.53% in Q4 2025, 35.57% in Q3 2025, and 35.55% in Q2 2025.